4 day week because of Presidents Day, but who cares. UTHR announced after market they initiated TreT Phase3 trial and that's huge for MNKD.
Many experts saying its a $1B+ drug annually and MNKD gets between 12%-15%, so we could be looking at a $150M annual revenue stream. Spencer's #'s from Seeking Alpha way to low. He doesn't like MNKD, but I agree a positive article for that dude.
So many catalysts and if this stock wasn't being attacked by the shorts we would have a $1B market cap right now. In fact it probably should be closer to $2B since that's what it takes to get a new drug thru FDA approval. We already have one Afrezza with another one on the way.
GL shorts you will need it. They are backing off as the borrow rate to short is down to 6% and short volume is declining. They are trapped and I think in the next two weeks this explodes up to at least $3.
Wainwright just came out today after market with a $4 price target which is way conservative.
News 
Market Data 
Discover 
